Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

Trial Title: Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

NCT ID: NCT06577987

Condition: Advanced Solid Tumor
Metastatic Solid Tumor
Refractory Solid Tumor
Cancer
Lung Cancer
Triple Negative Breast Cancer
Breast Neoplasms
Neuroendocrine Tumors
Neuroendocrine Carcinoma

Conditions: Official terms:
Neoplasms
Triple Negative Breast Neoplasms
Neuroendocrine Tumors
Breast Neoplasms
Carcinoma, Neuroendocrine

Conditions: Keywords:
Phase 1
CID-078
Estrogen

Study type: Interventional

Study phase: Phase 1

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: CID-078 Monotherapy
Description: Cyclin A/B-RxL inhibitor, twice-a-day in repeating 21-day treatment cycles until disease progression or discontinuation criteria.
Arm group label: Part 1 Dose Escalation and Part 2 Dose Expansion

Summary: This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.

Detailed description: This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL (Arginine-any amino acid-lysine) inhibitor, in patients with advanced solid tumors. The study will be conducted at approximately 10 centers. CID-078 will be evaluated as an oral therapeutic. This study is divided into two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. There is also a pilot food effect cohort to evaluate the effect of food on CID-078 pharmacokinetics (PK) profile. The Dose Escalation (Part 1) component of the study will evaluate safety and identify recommended dose(s) for expansion (RDEs) of CID-078 using a Backfill Bayesian Optimal Interval design. Dose escalation will occur sequentially over several dose levels. Part 2 is a Dose Expansion in which eligible patients will be treated at the dose(s) selected in Part 1 to evaluate the anti-tumor efficacy of the study drug and further characterize its safety, tolerability, PK, and pharmacodynamics in patients with selected malignancies to be determined prior to opening Part 2. The study consists of a 28-day Screening Period, a Treatment Period, an End of Treatment (EOT) Visit, and a Safety Follow-up Visit. After confirming eligibility, patients enter the Treatment Period that consists of repeating 21-day treatment cycles. Study drug treatment cycles will continue for as long as the patient does not meet study drug discontinuation criteria. Within 7 days of the last dose of study drug or the decision to withdraw from the study, patients will undergo an EOT visit and a Safety Follow-Up visit 28 days after the EOT visit.

Criteria for eligibility:
Criteria:
Inclusion Criteria: A patient must meet all of the following inclusion criteria to be eligible to participate in this study. 1. Locally advanced or metastatic solid tumor malignancy that has progressed or was nonresponsive to available therapies and for which no standard or available curative therapy exists. 2. Patients with Small Cell Lung Cancer (SCLC) and Non-small Cell Lung Cancer (NSCLC) must have measurable disease per RECIST v1.1. All other patients that do not have SCLC or NSCLC must have evaluable, but do not have to have measurable disease. a. Patients with Breast Cancer (BC) enrolling on backfill (BF) cohorts must have measurable disease by RECIST v1.1. 3. Age ≥ 18 years. 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 5. Life expectancy greater than 12 weeks. 6. Ability to swallow capsules by mouth. 7. Have the following laboratory values: 1. Calculated creatinine clearance (CrCl) ≥ 60 mL/min/1.73 m^2 (by Cockroft-Gault formula); actual body weight must be used for CrCl unless Body Mass Index (BMI) > 30 kg/m^2 then lean body weight must be used. 2. Total bilirubin ≤ 1.5 × ULN unless prior history of Gilbert's syndrome with Sponsor Medical Monitor approval 3. Aspartate transaminase and alanine transaminase ≤ 2.5 × upper limit normal (ULN), or ≤ 5 × ULN if due to liver involvement by tumor 4. Hemoglobin ≥ 9.0 g/dL (last transfusion > 14 days prior to Cycle 0 Day 1/ Cycle 1 Day 1) 5. Platelets ≥ 100 × 10^9 cells/L (last platelet transfusion > 14 days prior to C0D1/C1D1) 6. Absolute neutrophil count ≥ 1.2 ×10^9 cells/L (last dose of hematopoietic growth factors >14 days from Cycle 0 Day 1/ Cycle 1 Day 1) 8. Male and female patients must be surgically sterile or commit to sexual abstinence or use 2 acceptable forms of birth control methods. 9. Women of child-bearing potential must have a negative serum pregnancy test during Screening and a negative urine or serum test prior to Cycle 0 Day 1/ Cycle 1 Day 1. Exclusion Criteria: A patient who meets any of the following exclusion criteria will be ineligible to participate in this study. 1. Treatment with any of the following: 1. Targeted therapy ≤ 8 days or 5× the terminal phase elimination half-lives, whichever is shorter, prior to Cycle 0 Day 1/ Cycle 1 Day 1. 2. Systemic anticancer treatment (excluding targeted therapy as described above) ≤ 14 days prior to Cycle 0 Day 1/ Cycle 1 Day 1. 3. Radiotherapy ≤ 28 days and palliative radiation ≤ 14 days prior to Cycle 0 Day 1/ Cycle 1 Day 1. 4. Immunotherapy ≤ 28 days prior to Cycle 0 Day 1/ Cycle 1 Day 1. 5. Major surgery ≤ 28 days prior to Cycle 0 Day 1/ Cycle 1 Day 1. 2. Have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation. Patients with chronic, but stable Grade 2 toxicities may be allowed to enroll after agreement between the Investigator and Sponsor Medical Monitor. 3. Have known or suspected brain metastases or spinal cord compression, unless the condition has been asymptomatic and treated. 4. Past medical history of interstitial lung disease, or any evidence of clinically active interstitial lung disease. 5. Patient has a history of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification or serious cardiac arrhythmias requiring treatment. 6. QTc interval (using Fridericia correction calculation) > 470 msec. 7. Current treatment with medication known to prolong the QT/QTc (corrected QT) interval or history of additional risk factors for Torsade de Pointes. 8. Pregnant or lactating women. 9. History of another primary malignancy ≤ 2 years prior to Cycle 0 Day 1/ Cycle 1 Day 1, except for adequately treated cancer. 10. Malabsorption syndrome or other conditions that may interfere with adequate absorption of investigational product. 11. Uncontrolled intercurrent illness including, but not limited to, uncompensated respiratory, cardiac, hepatic, or renal disease, active infection (including untreated HIV and active clinical tuberculosis), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 12. Current endocrinopathies, unless in the opinion of the investigator endocrine complications are stable and well controlled and study participation does not jeopardize patient's risk. 13. Prior solid organ transplantation

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: START Midwest

Address:
City: Grand Rapids
Zip: 49546
Country: United States

Status: Recruiting

Facility:
Name: NEXT Oncology

Address:
City: San Antonio
Zip: 78229
Country: United States

Status: Recruiting

Facility:
Name: START Mountain

Address:
City: West Valley City
Zip: 84119
Country: United States

Status: Recruiting

Start date: August 14, 2024

Completion date: March 14, 2027

Lead sponsor:
Agency: Circle Pharma
Agency class: Industry

Source: Circle Pharma

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06577987